FOR IMMEDIATE RELEASE: SEATTLE | April 6, 2018: As IDRI (Infectious Disease Research Institute) celebrates its 25th
anniversary in 2018, the organization is developing a strategic plan to hone current strengths while embarking upon bold new initiatives including next generation vaccine adjuvants and formulations, as well as RNA vaccines. To strengthen our leadership team and achieve that plan, IDRI has named Richard Lautch, a senior financial executive who had a 15-year career with Starbucks before serving as a consultant in the biotech industry for the past two years, as its Chief Operating Officer. A member of IDRI’s Board of Directors for the past year, Lautch will oversee all aspects of IDRI administrative operations, including finance, in his new role.
Additionally, IDRI named Corey Casper, MD, MPH, as its Chief Scientific Officer to lead scientific operations and execute the scientific strategy for the organization. Casper joined IDRI in 2017 as its Chief Medical Officer after serving in various roles at the Fred Hutchinson Cancer Research Center and the University of Washington, where he remains a Professor of Medicine and Global Health. He will also continue to oversee all medical activities for IDRI.
“During the last year I’ve had the opportunity to observe IDRI at close hand,” said Lautch. “There is so much wonderful science here and a very strong team. I see my new role as helping IDRI navigate along the path of bringing these exciting discoveries to treatments that can be delivered to patients in areas of need. That will require us to be strategic in where we focus our efforts, working together with existing partners and forming new alliances to help us advance. I’m extremely excited to be joining IDRI on that journey.”
A financial leader with experience during rapid company growth and change, Lautch has served as a biotech consultant, advising on business strategy and development for both U.S. and emerging markets. Lautch also served as Vice President Finance, Treasurer – Finance Administration at Starbucks, where he played an instrumental role in growing revenues from less than $2 billion to more than $15 billion with a global footprint that expanded from 4 to 64 countries. While at Starbucks, Lautch played key roles in capital structure and financing, financial planning and analysis, investment strategy, relationship management and impact investing. He also served in a variety of leadership roles ranging from being a member of Starbucks’ Capital Committee to serving as chairman of Starbucks Card Europe Ltd.
“Richard’s familiarity with IDRI, combined with extensive experience in financial and international operations, will be a valuable addition to our organization as we continue to explore innovative ways to fulfill our mission,” said Steve Reed, PhD, IDRI President, CEO & Founder. “Likewise, Corey is very familiar with IDRI’s science; after being on our team for nearly a year, he is extremely qualified to enable IDRI’s new initiatives. Together, Richard and Corey will bring together the administrative and scientific components of IDRI to perform at the highest level in service of our mission.”
Prior to joining Starbucks in 1999, Lautch spent 12 years in investment banking roles while at Banco Santander, BNP Paribas and National Westminster Bank.
Lautch holds a degree in electrical and electronic engineering from the University of Bath in England. He serves on the finance committees for The Grameen Foundation and the Washington Chapter of the Nature Conservancy.
About IDRI: As a nonprofit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit www.idri.org.
IDRI: Lee Schoentrup | 206.858.6064 | email@example.com